Fitzsimons Innovation Community is an integrated urban campus where health and life sciences companies of all sizes work on their next big things. Our customized workspace, collaborative campus, and proximity to one of the top health systems and medical schools in the country make our community the perfect place to put down roots and get to work.
MOVE-IN READY LAB SPACE
GROWTH OPPORTUNITIES
Coming soon
It’s not just additional space—it’s fifty sprawling acres of additional space. And it’s primed for ultra-custom, made-to-order facility development.
Fitzsimons Innovation Community and University of Colorado Anschutz Medical Campus working together.
Relationships that help you thrive.
An urban mountain lifestyle for work and play.
Everything you need.
Right here.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
Fitzsimons Innovation Community releases its Second Annual Innovation Report focused on the momentum our Community members build on our campus to take their discoveries and projects from idea to market.
The company’s off-the-shelf or ‘allogeneic’ therapy tabelecleucel – now given the Ebvallo trade name – has been approved by the European Commission as a second-line treatment for a rare and potentially deadly cancer that afflicts some organ or bone marrow transplant recipients.
The University of Colorado Anschutz Medical Campus has been named one of the top academic institutions in the world for innovation, according to Nature’s 2022 Innovation Index report. The report ranked CU Anschutz in the top four universities globally for forging the strongest innovations links.
Colorado BioScience Association today announced annual fundraising totals for the state’s life sciences ecosystem. Companies, organizations, and researchers in the state’s life sciences community raised $1.6 billion in 2022, marking the sixth year fundraising totals hit more than $1 billion. The numbers are consistent with life sciences funding trends across the U.S., with activity remaining strong but returning to pre-pandemic levels following a record-breaking 2021.
Bringing together industry partners, entrepreneurs, and investors to help CU researchers and healthcare practitioners solve important medical problems and improve the quality of life for patients worldwide. We strive to enable healthcare advancements and scientific research that will benefit society, while also generating a sustainable revenue stream for the University.
A conversation with Melissa Krebs, CEO and Founder of GelSana and Associate Professor at Colorado School of Mines.
The award recognizes the investments Fitzsimons Innovation Community is making to advance Colorado’s life sciences community and better position the entire ecosystem for growth
Congresswoman Diana DeGette (D-CO) visits the Gates Biomanufacturing Facility's Protein Suite, in which GMP-grade AV-1980R was manufactured for the Institute for Molecular Medicine's phase 1 clinical...
Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.
Rather than just redirecting flow, implantations provide therapy to heart cells and drive new tissue
Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).
Fitzsimons Innovation Community
